In this retrospective study, we found that a risk model based on platelet count < 33.5*109/L, IL-6 > 20.79 pg/mL, IFN-γ > 12.12 pg/mL, and IL-10 > 39.87 pg/mL can effectively differentiate EBER-positive LAHS from non-neoplastic EBV-HLH. This evidence concerns the gene IL6 and hemophagocytic syndrome.